Elotuzumab-g2a and anti–PD-1 combination promotes NK cell activation and cytokine and chemokine release within A20-hSLAMF7 tumors. A20-hSLAMF7–bearing mice were treated with control, 3 mg/kg anti–PD-1, 10 mg/kg elotuzumab-g2a (Elo), or elotuzumab-g2a plus anti–PD-1. Tumor-infiltrating and splenic NK cells were analyzed by flow cytometry. Results are a composite of 3 independent experiments with a total of 9 to 15 mice per group unless indicated otherwise. NK cells were gated as live, GFP⁻CD19⁻CD3⁻NKp46⁺. (A-B) Quantification of (A) IFN-γ–producing and (B) TNF-α–producing tumor-infiltrating and splenic NK cells as percentages of total NK cells isolated 4 to 7 days after the start of treatment. (C) Intratumoral concentration of MIP-1β in tumors isolated 5 days after the start of treatment, measured by enzyme-linked immunosorbent assay. n = 5 per group. (D-E) Quantification of (D) CD107a⁺ and (E) CD69⁺ tumor-infiltrating and splenic NK cells as percentages of total NK cells isolated 10 to 14 days after the start of treatment. Results are shown as mean ± SEM. Statistical analyses were performed by using ANCOVA (A-B,D-E) and unpaired Student t test (C). *P < .05; ** P < .01; ***P < .0001.